The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

This study has been terminated.
(This study was terminated early in May 2006 due to low patient enrollment)
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: September 12, 2005
Last updated: April 19, 2012
Last verified: April 2012
Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.

Condition Intervention Phase
Constipation Predominant
Irritable Bowel Syndrome (IBS-C)
Drug: Tegaserod
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • To evaluate the effects of tegaserod on motility and small intestinal flow patterns after meal in female patients with IBS-C
  • by using Multiple Intraluminal Impedance

Estimated Enrollment: 20
Study Start Date: November 2004
Study Completion Date: May 2006
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female 18 and older
  • IBS-C patients diagnosed on the basis of Rome II criteria
  • Ability to comply with the requirements of the entire study

Exclusion Criteria:

  • Evidence of structural abnormality of the gastrointestinal tract or disease/conditions.
  • Patients with previous gastrointestinal surgery other than appendectomy or cholecystectomy.
  • Evidence of cathartic colon or a history of laxative use, that in the investigator's opinion is consistent with severe laxative dependence such that the patient is likely to require or use laxatives during the study

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00171431

United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Novartis
  More Information

Responsible Party: Novartis ( Novartis Pharmaceuticals ) Identifier: NCT00171431     History of Changes
Other Study ID Numbers: CHTF919AUS33 
Study First Received: September 12, 2005
Last Updated: April 19, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:

Additional relevant MeSH terms:
Irritable Bowel Syndrome
Colonic Diseases
Colonic Diseases, Functional
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Pathologic Processes
Signs and Symptoms
Signs and Symptoms, Digestive
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Serotonin Agents
Serotonin Receptor Agonists processed this record on May 22, 2016